Lexicon Pharmaceuticals (LXRX) Investor presentation summary

Strategic objectives and pipeline progress

• Advancing late-stage sotagliflozin programs in hypertrophic cardiomyopathy (HCM) and type 1 diabetes (T1D), with global expansion efforts and ongoing collaborations for broader reach.

• Enrollment for the SONATA-HCM Phase 3 study is on track for mid-2026 completion, with topline data expected in Q1 2027.

• Preparing for NDA resubmission for ZYNQUISTA in T1D, supported by new clinical data and strong community backing.

• LX9851 Phase 1 study for obesity initiated by Novo Nordisk, with milestone payments received and further milestones anticipated.

• Pilavapadin advancing toward Phase 3 for neuropathic pain, with strategic options under evaluation and IND-enabling work for additional indications.

Sotagliflozin clinical and mechanistic highlights

• Dual SGLT1/2 inhibition offers unique cardiometabolic benefits, with SGLT1 upregulated in HCM and acting directly on the myocardium.

• SONATA-HCM Phase 3 targets both obstructive and non-obstructive HCM, with primary endpoint focused on quality of life improvement.

• Data from SOTA-P-CARDIA and other studies show significant improvements in symptoms, functional capacity, and reduction in epicardial fat in non-diabetic HFpEF patients.

• Sotagliflozin positioned as a potential first-line oral therapy for symptomatic HCM, with no REMS required.

Pilavapadin and chronic pain innovation

• Pilavapadin targets AAK1, a novel mechanism for neuropathic pain, validated in preclinical and clinical studies.

• Phase 2b results support 10 mg dose selection for Phase 3 in diabetic peripheral neuropathic pain (DPNP).

• Significant unmet need in DPNP, with most patients dissatisfied with current options and seeking non-opioid alternatives.

• Supportive regulatory and legislative environment for non-opioid pain therapies, with new guidance and expanded Medicare access.

• Successful End-of-Phase 2 FDA meeting, with optimized Phase 3 protocol and ongoing strategic evaluations.